Cerulean Grabs $24 Million for Nano Drugs

Tiny drugs just got a big endorsement. Cambridge, Mass.-based Cerulean Pharmaceuticals has closed a $24 million Series C funding round to fuel development of its nanoparticle drugs, the company announced Monday.
Xconomy